Search

This in vitro study aimed at investigating the possible radioprotective effects of natural substances propolis and quercetin on gamma-irradiated human white blood cells. The levels of primary DNA damage were studied by the alkaline comet assay, while the cytogenetic damage was evaluated using the analysis of structural chromosome aberration and cytokinesis-block micronucleus assay. The results obtained by all endpoints indicate acceptable toxicity profiles of propolis and quercetin in vitro, and also confirmed their radioprotective abilities. Propolis was found to be more effective in diminishing the levels of primary and more complex cytogenetic DNA damage in gamma-irradiated white blood cells. Data gathered in present study support the use of propolis and quercetin as non-toxic protective substances. However, to clarify the underlying mechanisms of their cyto/radioprotective activities, additional studies are necessary at both in vitro and in vivo levels.

Radioprotective effects of amifostine and melatonin as well as their ability to modulate the level of spontaneous and gamma-irradiation-induced genetic changes on human peripheral blood lymphocytes were investigated using the cytokinesis-block micronucleus (CBMN) assay and sister chromatid exchange (SCE). Parallel blood samples were pre-treated with amifostine, melatonin and their combination for 30 minutes. Negative controls were also included. After the treatment with radioprotectors, one blood sample of each experimental group was exposed to gamma-rays from a 60Co source. The radiation dose absorbed was 2 Gy. Our research confirmed the radioprotective effects of both chemicals in vitro, with no significant genotoxicity. Pre-treated irradiated blood samples showed a decrease in the total number of micronuclei (MN) and in the number of cells with more than one MN. They also showed significantly lower mean SCE values. This study shows that it is possible combine these radioprotectors by adjusting the doses of amifostine to achieve the best radioprotective effect with as few side effects as possible. However, further in vitro and clinical studies are needed to clarify their mechanisms of action and possible interactions.

A 47-year-old woman was referred for the treatment to our Hospital because of a palpable nodule in the upper medial quadrant of her right breast. After tumor excision, pathohistological examination showed a follicular center cell lymphoma grade 2, B-cell type (CD20+, bc16+, CD10+, bcl2+). The final diagnosis was stage IEA primary extranodal non-Hodgkin s breast lymphoma. The involved breast was irradiated isocentrically with two opposite 6-megavolt (MeV) photon beams delivered from the linear accelerator (tangential fields) using asymmetric collimator opening. Radiation volume, inclinations of the medial and lateral field, and the part of the underlying chest wall and lung parenchyma were determined during the radiotherapy simulation process. The total irradiation dose was 44 Gy delivered in single daily doses of 2 Grays (Gy). After breast photon irradiation, a boost to the tumor bed was performed by a direct 12 MeV electron beam, with a total dose of 6 Gy delivered over three days. Since primary non-Hodgkin lymphoma of the breast is rather rare, there has been no uniform approach to its treatment. The advantage of applying the asymmetric collimator jaw opening in breast radiotherapy is the instant reduction of the dose at margin fields, resulting in both the protection of neighboring lung parenchyma and the good coverage of planned target volume.